Cellarity, a biotechnology company developing cell state-correcting therapies through integrated multi-omics and AI modeling, ...

Academic scientists and pharmaceutical companies alike are embracing artificial intelligence, even as questions linger about ...

This Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare. But Is It a Buy? Veeva Systems markets a suite ...

The drug development pipeline is a costly and lengthy process. Identifying high-quality "hit" compounds—those with high ...

A researcher has proposed a more targeted approach to AI drug discovery, which includes a rigorous evaluation protocol.

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

The UK is facing a pharma exodus. Major pharmaceutical companies have withdrawn about £2 billion in proposed investment from ...

Traditionally, developing a new drug takes many years and requires a massive financial investment, often involving significant risk and a high likelihood of failure. AI models trained on extensive ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...